Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Combinations of the human immunodeficiency virus (HIV) Tat protein antagonist Ro 24-7429 with either the HIV protease inhibitor Ro 31-8959 or the HIV reverse transcriptase inhibitors AZT (3'-azido-3'-deoxythymidine), ddC (2',3'-dideoxycytidine), ddI (2',3'-dideoxyinosine), and nevirapine were synergistic or additive in reducing HIV type 1 p24 antigen production in CEM cells or inhibiting HIV type 1-induced syncytium formation in HT4-6C cells.
Connell
E V
EV
Department of Virology, Hoffmann-LaRoche Inc., Nutley, New Jersey 07110.
Hsu
M C
MC
Richman
D D
DD
D000998:Antiviral Agents / Q000494:pharmacology*; D001569:Benzodiazepines / Q000494:pharmacology*; D016049:Didanosine / Q000494:pharmacology; D004357:Drug Synergism; D015696:Gene Products, tat / Q000037:antagonists & inhibitors*; D006678:HIV / Q000187:drug effects / Q000201:enzymology; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology*; D019829:Nevirapine; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles; D011804:Quinolines / Q000494:pharmacology*; D018894:Reverse Transcriptase Inhibitors; D019258:Saquinavir; D016047:Zalcitabine / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology; D054322:tat Gene Products, Human Immunodeficiency Virus
D000998:Antiviral Agents; D015696:Gene Products, tat; D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011725:Pyridines; D011758:Pyrroles; D011804:Quinolines; D018894:Reverse Transcriptase Inhibitors; D054322:tat Gene Products, Human Immunodeficiency Virus; D001569:Benzodiazepines; C070024:Ro 24-7429; D015215:Zidovudine; D016047:Zalcitabine; D019829:Nevirapine; D016049:Didanosine; D019258:Saquinavir